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Introduction
Insomnia is the most common sleep disorder with an estimated prevalence ranging from 8% to 20% in adults [1] [2] [3] . Complains in impaired daytime functioning, such as difficulties in decision making, decreased concentration and memory, and increased mistakes during work, are quite common in people with insomnia and lead to the most insomnia-related costs, in which several cognitive domains are involved [4, 5] . However, studies comparing the cognitive performance on neuropsychological tasks between individuals with and without insomnia have produced contradictory findings, which might be due to the variant measurements used in different studies, insensitive tools failing to detect mild cognitive deficits, and the lack of objective criterion of insomnia [6, 7] .
The diagnosis of insomnia is solely based on self-reported complaints including difficulties in initiating or maintaining sleeping, early awakening, and daytime fatigue [8] . Recently, increasing evidence suggests that insomnia with objective short sleep duration (SSD), characterized by the hyperarousal of hypothalamic-pituitary-adrenal (HPA) and sympatho-adrenalmedullary axes, both limbs of stress system, might be the most severe phenotype of insomnia, which is associated specifically with higher risk for medical morbidity, such as hypertension, diabetes, and neurocognitive impairment [9] . In Mendoza et al.'s study, people with insomnia with objective SSD performed worse on neuropsychological tasks compared with healthy controls with SSD, which implies that the cognitive deficits of people with insomnia are more likely associated with hyperarousal rather than just sleep loss [10] .
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that is involved in neurogenesis and neuronal survival, and it has been shown to be a central mediator of the effects of stress on neuroplasticity [11, 12] . There is evidence showing that BDNF level could be regulated by the HPA function. The deregulation of HPA, which may be triggered by chronic insomnia, would lead to a decreased peripheral BDNF level [13] . In previous studies, BDNF has been found to participate both in pathogenesis of mental disorders like depression and regulation of learning, memory, and sleep [14] [15] [16] . Giese's pilot study with a small sample of 26 people with insomnia and 24 healthy controls suggests that peripheral BDNF could be considered as a biomarker for subjective insomnia, and the severer of insomnia, the lower of serum BDNF level [17] . Therefore, whether BDNF is associated with the cognitive impairment of insomnia and whether this relationship is moderated by the objective sleep duration warrant further discussion. Thus, in the present study, we comprehensively tested the effects of primary insomnia (PI) with different objective sleep durations measured by polysomnography (PSG) on neuropsychological performance and further explored whether this effect was associated with BDNF levels.
Materials and Methods

Participants
The patients were screened from the Peking University Sixth Hospital, Beijing, China. The healthy controls were recruited by advertising from the community. In consistent with previous studies, we divided insomnia patients into two groups: the SSD group included people with insomnia who had a sleep time of <6 hr and normal sleep duration (NSD) group had a sleep time of ≥6 hr based on the objective sleep time data collected by PSG.
Finally, 57 patients (n = 30 in SSD group and n = 27 in NSD group) with PI and 29 age-, gender-, and education level-matched healthy controls were recruited. All participants were Han Chinese people and signed consent forms before participation. The study was approved by the ethics committee of Peking University Sixth Hospital. People with PI were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. All participants have not received any medication for at least 2 weeks prior to the study. Exclusion criteria include (1) brain trauma and neurological disorders with cognitive dysfunction; (2) obstructive sleep apnea and other comorbid-sleep disorders; (3) dementia and neurodevelopmental disorders; (4) current and life time history of any psychiatric disorders; (5) severe physical diseases including cancer, rheumatism, diabetes, stroke, and epilepsy, and other diseases involving thyroid, liver, kidney, lung, cardiovascular, endocrinal, and nervous system (6) rotating shift work with overnight shifts; (7) current smoking of ≥10 cigarettes per day; (8) alcoholics and drug abuser; and (9) women who is in pregnancy, menstrual, or breast feeding period.
All participants underwent a clinical interview by an experienced psychiatrist and were assessed the current or previous history of any psychiatric disorders based on the Chinese version of Mini-International Neuropsychiatric Interview [18, 19] , Hamilton Depression Scale (HAMD) [20] , and Hamilton Anxiety Scale (HAMA) [21] .
Subjective sleep assessment
Epworth Sleepiness Scale (ESS) was a self-rated questionnaire used to measure excessive sleepiness in the daytime. The participants were asked to rate the likelihood of sleepiness in eight different situations on a four-point Likert scale from 0 to 3 (0 = no, 1 = slight, 2 = moderate, and 3 = high chance of dozing). The sum score ranges from 0 to 24. A higher score means more likely to fall asleep. The Chinese version of ESS has been proved with good reliability and validity [22] .
Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1 month time interval. PSQI measures seven different dimensions of sleep, which are subjective sleep quality, sleep latency, sleep duration, habitual sleep efficacy, sleep disturbances, sleep medication, and daytime dysfunction, using 19 individual items. The component score for each dimension is weighted on a 0-3 Likert scale. The sum of seven component scores generates a global PSQI score ranging from 0 to 21; a higher score represents poorer subjective sleep quality. The Chinese version of PSQI shows good psychometric properties in people with primary insomnia [23] .
Flinders fatigue scales (FFS) is a 7-item self-report scale which measures daytime fatigue over past 2 weeks. Six items are scored in Linkert scale ranging from 0 (not at all) to 4 (extremely). Item 5 is a multichoice question scored by the sum number of choices (0-7). The item scores are summed to provide a total fatigue score ranging from 0 to 31, with higher scores indicating greater fatigue. The FFS has strong psychometric properties in people with insomnia [24] .
Neuropsychological assessment
All participants underwent a comprehensive neuropsychological test battery based on the MATRICS (the measurement and treatment research to improve cognition in schizophrenia) Consensus Cognitive Battery (MCCB), by which seven domains of cognitive function were evaluated, including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem-solving, and social cognition [25] . The Chinese version of MCCB has demonstrated good reliability and validity in community samples in mainland China [26] . The MCCB procedure was operated according to the following order: (1) [33] .
Polysomnography
The PSG of participants was evaluated for one night in the sleep monitoring center in sound-attenuated, light-, and temperaturecontrolled rooms. Particiapnts were required to arrive at least 2 hr before sleep monitoring to get familiar with the environment. Bedtime was adjusted according to participants' usual habits and whole-night PSG (8 hr) was recorded between 22:00-23:00 and 6:00-7:00. Daytime sleep was prohibited. The polysomnographic recording met the guidelines of the American Academy of Sleep Medicine [34] . The monitoring was conducted using a polysomnography system (Alice 6, Philips) including six electroencephalograph leads (F3, F4, C3, C4, O1, and O2, connecting mastoid), bilateral electrooculogram leads, anterior tibialis and submentalis electromyogram leads, and electrocardiogram. Respiratory rhythm monitoring included oronasal airflow, chest and abdominal breathing efficiency, and oxygen saturation. Sleep time was visually scored by a specialized technician and was reviewed by a neurologist. We collected data for total sleep time (TST), sleep onset latency (SOL), the percentage of each sleep stage (N1%, N2%, N3%, and REM%), sleep efficiency, and apnea-hypopnea index (AHI).
BDNF detection
Single fasting blood was collected between 7:30 and 8:00 in the next morning of PSG monitoring using a serum separator tube from the antecubital vein. Serum samples were prepared after the blood was clotted for 1 hr at room temperature and 1 hr at 4°C followed by centrifugation at 3000 × g for 30 min at 4°C. Serum samples were stored at −80°C until assaying. Serum BDNF levels were measured using enzyme-linked immunosorbent assay kit according to the manufacturer's instruction (Promega BDNF Emax). The absorbance was measured within 30 min using Multiskan microplate reader (ThermoFisher Scientific) at 450 nm to determine BDNF concentrations. All assays were performed in duplicate.
Statistical analysis
Data in bar chart and table are presented as the mean ± standard deviation (SD). The normal distribution of the data and the homogeneity of variances were tested using the Shapiro-Wilk and Levene's tests, respectively. Analysis of variance (ANOVA), Kruskal 
Results
The demographic characters and subjective sleep index
The sociodemographic characteristics including age, gender, body mass index, and education level were comparable among SSD, NSD, and healthy controls (all p > 0.05). The course of insomnia, which were 6.22 and 5.40 years, respectively, did not differ significantly between SSD and NSD groups (p = 0.480; Table 1 ). Next, the subjective sleep, anxiety, and depression status were compared among these three groups and significant differences were found on all these respects (all p < 0.01). Post hoc analysis showed that both SSD and NSD groups had higher PSQI, FFS, HAMA, and HAMD scores, while lower ESS scores, compared with the controls (all p < 0.01, Table 1 ). However, no significant differences were found between SSD and NSD groups in subjective sleep, depression, or anxiety status (all p > 0.05).
The comparisons of PSG characters
We found significant differences in SOL, TST, sleep efficiency, and N3% among three groups. To be specific, post hoc analysis revealed that both SSD and NSD groups had longer SOL, shorter TST, and decreased sleep efficiency compared with controls (all p < 0.05). Moreover, SSD group presented an even decreased TST and sleep efficiency compared with NSD group (all p < 0.001). In addition, people with SSD insomnia showed a decreased N3 phase compared with controls (p = 0.004), which was not presented in people with NSD insomnia (Table 1 ).
The cognitive performances
In the neuropsychological test battery, significant group effects were found on spatial span, BVMT, fluency, managing emotions, and CPT-IP (all p < 0.05, Figure 1) . Moreover, post hoc tests revealed that the SSD group had significant lower scores in spatial span (p = 0.004), BVMT (p < 0.001), fluency (p = 0.018), managing emotions (p = 0.002), and CPT-IP (p < 0.001) compared with controls. NSD group only perform worse in BVMT (p = 0.017) and CPT-IP (p = 0.025) compared with controls and with a higher score than SSD group in the latter test (p < 0.001). NSD group also showed better performance on fluency tasks compared with SSD (p = 0.035). Scores were not different in TMT, BACS-SC, and HVLT tests between the three groups (all p > 0.05; Table 1 ).
The correlations between sleep indexes and cognitive performance
In SSD group, the scores of managing emotions test correlated negatively with SOL (r = −0.47, p = 0.009) while positively with N3% (r = 0.43, p = 0.017). However, no significant correlation was observed between objective sleep indexes and neuropsychological test scores in NSD group (all p > 0.05). Subjective insomnia examined by PSQI, ESS, and FFS showed a different pattern compared with objective insomnia. Specifically, FFS score had a negative correlation with spatial span (r = −0.50, p = 0.005) and identical pairs scores (r = −0.56, p = 0.001) in SSD group but with BVMT score in NSD group (r = −0.41, p = 0.034). PSQI scores did not correlate with any neuropsychological performance in people with SSD insomnia (all p > 0.05). In contrast, PSQI score correlated negatively with managing emotions test scores in people with NSD insomnia (r = −0.40, p = 0.037).
Serum BDNF levels and cognitive performances in people with insomnia
Serum BDNF levels were collected in all participants. The difference of BDNF levels between three study groups was significant after controlling for HAMA and HAMD scores (F ( Figure 2) . In SSD group, BDNF levels correlated positively with scores of spatial span (r = 0.42, p = 0.020, Figure 3A) , BVMT (r = 0.50, p = 0.005, Figure 3B ), and CPT-IP (r = 0.42, p = 0.020, Figure 3C ). After adjusted for HAMA and HAMD scores, the correlation between BDNF level and cognitive performance remained significant (spatial span: r = 0.42, p = 0.026; BVMT: r = 0.50, p = 0.007; CPT-IP: r = 0.44, p = 0.019). No correlation was found between BDNF levels and any neuropsychological test in NSD group (all p > 0.05).
Discussion
Given that insomnia with SSD is suggested to be a biological severe subtype, we in this study examined the associations between PSG-measured objective sleep duration in insomnia and performances on a battery of neuropsychological tests, which were sensitive to even mild cognitive impairment and proved to have good reliability and validity in Chinese population [26] . We further explored the role of peripheral BDNF in this relationship. To the best of our knowledge, this is the first study addressing the associations between cognitive dysfunction in people with insomnia and serum BDNF levels.
People with insomnia with SSD showed worse cognitive performance than people with NSD
In the present study, we found deficits in neuropsychological performance in people with insomnia, especially the ones with objective SSD. Specifically, people with SSD insomnia had impairments in spatial span, BVMT, fluency, managing emotions, and CPT-IP, suggesting a deficit in nonverbal working memory [29] , visual learning and memory [30] , verbal fluency and information processing speed [31] , emotion management [32] , and concentration and attention [33] . Of note, impaired performance in spatial span, fluency, and managing emotions tests were exclusively presented in SSD but not in NSD group. The results are partly consistent with Fernandez-Mendoza's study on that people with insomnia with objective SSD have severer deficits in processing speed, attention, and visual memory and further added evidence to the impaired working memory and emotion management which were not assessed in Mendoza's study [10] . It is noteworthy that we assessed the emotion management in people with insomnia for the first time and found that people with insomnia with SSD have significant difficulty in this cognitive respect. A bidirectional relation has been revealed in previous studies between emotional disturbance and insomnia [35] . It is plausible that insomnia reinforces the hyperarousal of emotion, which in turn contributes to the maintenance of insomnia as well as increased risk of depression and anxiety. In line with this conception, both SSD and NSD groups revealed significant higher scores on HAMA and HAMD than healthy controls in our study. In addition, a decreased functional connectivity between the amygdala and insula, striatum, and thalamus has been found in previous fMRI study on primary insomnia, which provides a biological evidence on emotional dysfunction of insomnia [36] .
Consistent with the discrepancy observed between SSD and NSD groups, SOL correlated negatively with scores of managing emotions test only in SSD group and no correlation was observed between PSG data and neuropsychological test scores in NSD group. In contrast, subjective insomnia using self-evaluated questionnaires such as PSQI, ESS, and FFS presented a mixture of results and were unable to differentiate the severity of insomnia. There was a report showing that individuals with insomnia tend to overestimate time to fall asleep or time of being awake after sleep onset, and as a result, underestimate TST compared with PSG results [37] . It has been widely acknowledged that insomnia is a disorder, characterized by 24 hr hyperarousal [38] . Also, the degree of hyperarousal predicts insomnia severity and stress-related morbidities, e.g. hypertension and impaired cognitive functions [39, 40] . It is suggested that insomnia with SSD is a severer phenotype that associated with much higher activity of stress system, generally indicated by increased secretion of glucocorticoids, e.g. cortisol [9, 41] . Rodent studies found that chronic elevation of glucocorticoids could disrupt neuroplasticity and inhibit cell proliferation and neurogenesis even during adulthood, especially in hippocampus, a vital region implicated in various cognitive functions [41] .
It is suggested that performance on complex tasks which depends on the integrity of prefrontal cortex (PFC) was more likely to be affected by insomnia [42, 43] . Working memory is one of the cognitive functions that highly involved in complex tasks [44] . However, previous studies on working memory of people with insomnia have reported contradictory findings which might partly be due to the lack of objective assessment of insomnia. Given that insomnia with SSD is biologically severer than insomnia with NSD, it is reasonable that people with insomnia with SSD show specific deficits on working memory.
The cognitive dysfunction in people with insomnia with SSD was associated with decreased peripheral BDNF level
In the second part of the study, we investigated the relationship between objective sleep duration and serum BDNF levels in people with insomnia. The decreased serum BDNF level was found in SSD group but not in NSD group in comparison with controls, which is in line with the notion that insomnia with SSD is biologically severer.
In Giese et al.'s study, serum BDNF was suggested to be a biomarker of subjective insomnia and the decrease of BDNF was correlated with severity of insomnia; however, part of the participants in this study have a previous diagnosis of psychiatric symptoms other than insomnia [17] . In our study, we verified and extended previous study by showing decreased BDNF levels only in people with insomnia with objective SSD but not NSD. In addition, we provided an association between BDNF levels and insomnia per se since all of the patients were PI who were not comorbid with any psychiatric disorders like depression that was previously associated with BDNF levels. The result might be explained by the hypothesis that chronic insomnia, especially those with SSD, might induce over activation of HPA system and systemic inflammation, which in the long term decreases BDNF level [13] . The chronic activation leads to dysregulation of HPA axis that related to increased secretion of glucocorticoid, which not only decrease the brain BDNF level but also affect the BDNF function [45] [46] [47] . On the other hand, insomnia symptom and SSD also have a joint effect on systemic inflammation, which could induce a significant decrease in the expression of brain BDNF [13, 48] .
Moreover, we found that BDNF levels correlated with neuropsychological performance, i.e. spatial span, BVMT, and identical pairs tests, only in SSD group, which suggest that the impaired cognitive function in insomnia with SSD would be attributed to decreased BDNF concentrations. BDNF is a neurotrophin widely expressed in the central nervous system, including hippocampus, PFC, and amygdala, which are the key brain regions highly involved in cognitive functions [49] . It was proved in animal models that BDNF mediated long-term potentiation, which is the neuropsychological basis of spatial learning and memory [50, 51] . On the other hand, compared with people with insomnia with NSD, people with insomnia with SSD showed upregulated cortisol and adrenocorticotrophic hormone levels as well as hyperactivity of inflammatory factors, which indicated a higher hyperarousal of HPA system [52, 53] . It is shown that the deregulation of HPA would lead to a decreased peripheral BDNF level [13] . Thus, we concluded that the decreased BDNF level of SSD group would affect the neurogenesis in the hippocampus and PFC, which as a result impair cognitive function.
There are several limitations in the present study. Firstly, the cross-sectional study design prevents causal inference between serum BDNF levels and cognitive function in people with insomnia. To prove the causal relationship, a prospective cohort design is needed in the further study. Secondly, we cannot provide evidence that peripheral BDNF levels correspond to brain BDNF levels in this report. However, such links have been implicated in previous study. Klein et al.'s study indicated that blood BDNF levels reflect brain BDNF levels, especially in hippocampus, across different species [54] . In addition, accumulating clinical studies has proved peripheral BDNF as a potential biomarker of psychiatric disorders, including depression, schizophrenia, and antidepressant response [55] [56] [57] . Thirdly, we cannot provide evidence that BDNF levels are related to HPA axis dysregulation in the present study as stress hormones were not measured. Finally, the small sample size limited the explanation of present findings. Further studies with in a larger sample size are needed.
In conclusion, PI was associated with impaired neuropsychological performance and decreased BDNF levels especially in SSD group. And in people with insomnia with SSD, the severity of impaired cognitive functions was positively associated with reduction of serum BDNF concentrations. Our findings confirmed previous studies that objective measures of sleep duration could be served as a marker of biological severity of insomnia and BDNF may be an indicator of insomnia per se. In future studies, the role of BDNF in impaired cognitive functions of people with insomnia with SSD should be discussed further.
